Loading…

Loading grant details…

Completed NON-SBIR/STTR RPGS NIH (US)

Impact of Loss-of-function NADPH Oxidase Variants on B-Cell Activation in SLE

$611.4K USD

Funder NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES
Recipient Organization Seattle Children'S Hospital
Country United States
Start Date Feb 01, 2021
End Date Dec 31, 2025
Duration 1,794 days
Number of Grantees 1
Roles Principal Investigator
Data Source NIH (US)
Grant ID 11063055
Grant Description

PROJECT ABSTRACT Genome-wide association studies (GWAS) have identified immune pathways linked to the pathogenesis of systemic lupus erythematosus (SLE). However, despite these insights, our understanding of how individual genetic variants promote autoimmunity remains poor. Loss-of-function mutations in genes of the phagocytic

NADPH oxidase complex (NOX2), including NCF1 and NCF2, have been linked with the pathogenesis of SLE and other humoral autoimmune diseases. The current model for how reduced NOX2 activity promotes lupus development focuses on defects in the clearance of apoptotic material by phagocytic myeloid lineages. While

myeloid defects likely contribute to disease risk, we hypothesize that a parallel B cell-intrinsic mechanism underlies the profound increase risk of SLE in human carriers of NCF1 and NCF2 variants. In addition to the production of pathogenic autoantibodies, recent studies have demonstrated that B cells can promote lupus

pathogenesis by initiating immune tolerance breaks and facilitating the generation of spontaneous germinal centers (GC). The activation of autoreactive B cells in SLE requires B cell-intrinsic expression of the endosomal toll-like receptors TLR7 and TLR9, and our published and preliminary data show that reduced NOX2 activity

results in dysregulated endosomal TLR signaling by impacting non-canonical autophagy pathways. Based on these data, we hypothesize that a B cell-specific reduction in NOX2 activity will result in enhanced TLR- dependent GC formation and the development of humoral autoimmunity. We will test this idea via parallel in vivo

and in vitro mechanistic studies. In Aim 1, we will test whether B cell-intrinsic deletion NOX2 component genes results in enhanced TLR-dependent GC responses using a well-characterized model of viral infection. In Aim 2, we will study whether reduced NOX2 activity promotes autoantibody production and humoral autoimmunity in

murine SLE. Finally, in Aim 3, we will use biochemical and cell imaging approaches to test whether NAPDH oxidase activity impacts B cell TLR signaling and non-canonical autophagy pathways using both murine genetic models and gene-edited human B cells. This supplemental research proposal will extend these proposed

Specific Aims and test a new hypothesis that loss of Wiskott-Aldrich syndrome protein similarly impacts B cell endolysosomal trafficking, resulting in enhanced TLR signaling. Together, these studies promise to advance our understanding of B cell biology and mechanisms underlying the pathogenesis of humoral

autoimmunity, allowing the candidate to receive clinically-relevant scientific training in support of their long-term career goals.

All Grantees

Seattle Children'S Hospital

Advertisement
Apply for grants with GrantFunds
Advertisement
Browse Grants on GrantFunds
Interested in applying for this grant?

Complete our application form to express your interest and we'll guide you through the process.

Apply for This Grant